BioSpace News Archive

A germ-zapping robot called LightStrike from Xenex is used at California Pacific Medical Center hospitals to help curb the spread of infectious diseases.

Diplomat Pharmacy, Inc. (NYSE: DPLO), is expanding its strategic relationship with medication adherence company SMRxT, creator of the Nomi® system.

Encompass Health Corp. (NYSE: EHC), a national leader in integrated healthcare, offering facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies, today reported its results of operations for the first quarter ended March 31, 2019.

Researchers and scientists analyzing crystallized protein samples in life sciences and materials research can now benefit from the first commercially released integrated solution for performing micro electron diffraction (MicroED), an advanced technique that enables researchers to quickly resolve structures up to a billion times smaller than those needed using traditional methods.

Celgene Corporation (NASDAQ:CELG) reported net product sales of $4,024 million for the first quarter of 2019, a 14 percent increase from the same period in 2018

Teva Pharmaceuticals USA, Inc. has initiated a voluntary recall in the United States, to the patient level, of 35 lots of bulk Losartan Potassium USP Tablets (6 lots of 25 mg strength and 29 lots of 100 mg strength).

A new 10-point manifesto from a leading research institute is calling for action to speed up access to innovative cancer drugs as an accompanying survey of 1,000 cancer patients finds many face barriers in receiving the latest treatments.

The Board of Directors of Sensient Technologies Corporation has declared a regular quarterly cash dividend on its common stock of $0.36 per share.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline findings from the final analysis of the pivotal Phase 3 KEYNOTE-062 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy (cisplatin and either 5-fluorouracil or capecitabine) for the first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

A custom risk control solution to monitor insurance coverage of General Contractor subs